Investor Presentaiton

IFNy spots/ 106 splenocytes 10000 1000 100 10 sanofi Innovative multi-antigen vaccine candidate achieves targeted immune profile, moving to phase 1/2 in 2024 Broad cross-serovar T cell responses Serovar D Serovar E Serovar F Serovar G Antigen A LNP only Spleen cells secreting Interferon-gamma in mice immunized with mRNA encoding Antigen A, or empty LNP control Serovar equates to serotype terminology in chlamydia field 103 Vaccines Investor Event ELISA titer anti-EB (log10EU) w Antigen B Cross-serovar antibodies recognizing native elementary bodies LNP only Serovar D Serovar E Serovar G ELISA titer anti-EB (log10EU) Antigen C Serovar D Serovar E Serovar G T Antigen D LNP only Elementary body (EB) binding antibodies in sera from mice immunized with mRNA encoding Antigen B, C, D or empty LNP control

View entire presentation